These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22581207)

  • 1. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
    Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
    Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
    Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
    J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
    Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
    Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.
    Seror V; Cao C; Roussey M; Giorgi R
    J Med Screen; 2016 Jun; 23(2):62-9. PubMed ID: 26304152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP.
    Teper A; Smithuis F; Rodríguez V; Salvaggio O; Maccallini G; Aranda C; Lubovich S; Zaragoza S; García-Bournissen F
    Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.
    Sarles J; Giorgi R; Berthézène P; Munck A; Cheillan D; Dagorn JC; Roussey M
    J Cyst Fibros; 2014 Jul; 13(4):384-90. PubMed ID: 24513262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis.
    Sarles J; Barthellemy S; Férec C; Iovanna J; Roussey M; Farriaux JP; Toutain A; Berthelot J; Maurin N; Codet JP; Berthézène P; Dagorn JC
    Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F118-22. PubMed ID: 10325788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net.
    Sommerburg O; Stahl M; Hämmerling S; Gramer G; Muckenthaler MU; Okun J; Kohlmüller D; Happich M; Kulozik AE; Mall MA; Hoffmann GF
    J Cyst Fibros; 2022 May; 21(3):422-433. PubMed ID: 34764021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
    Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
    Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
    [No Abstract]   [Full Text] [Related]  

  • 15. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
    Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
    Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
    Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
    Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
    Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
    Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
    Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
    J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.